SAM 2023 will cover a broad range of topics, including:
- attention deficit hyperactivity disorder,
- and aromatherapy.
The programme and schedule will be posted online as quickly as possible. Please check back soon or contact the organising committee at
NOTE: Please note that the schedule and programme may change without prior notice. If a speaker/trainer is unavailable, they will be replaced by a speaker/trainer with a similar profile.
La traduction à la Direction européenne de la qualité du médicament & soins de santé (EDQM)
|Following a short presentation of the EDQM, you will learn about how the linguistics department is organised, the tools it uses, the types of texts it handles and its processes, as well as a typical “day in the life” and what I learned on becoming a translator at the EDQM after being a freelance translator.
Advanced Therapy Medicinal Products
|Dr Ed Zanders
|Most approved medicines are small chemical molecules that can be administered orally, although currently the majority of the top ten best-selling branded drugs worldwide are large proteins, such as monoclonal antibodies. Not so long ago, pharmaceutical companies were reluctant to develop drugs of this type because of the complexity and expense associated with biological products. Now this is happening all over again, this time with highly complex biotech medicines. These advanced therapy medicinal products (ATMPs) are classified by the European Medicines Agency (EMA) as “a medicine for human use that is based on genes, cells or tissue engineering”. ATMPs promise to treat previously intractable diseases despite the technical and commercial risks for large pharmaceutical companies who have the resources to develop them.
This presentation will focus on two examples of genetically modified cells, namely chimeric antigen receptor (CAR) T-cells for cancer and CRISPR/Cas9. I shall cover the technicalities of engineering DNA constructs and introducing them into human cells while maintaining the high degree of quality control required for administration of such modified cells to patients.
The CAR T cell example is Kymriah®, produced by Novartis for treating childhood leukaemia and lymphomas. The relevant EMA documentation will be used as a guide to some of the issues in manufacturing and clinical use arising with this novel treatment.
The second example is CTX-001 under co development with CRISPR Therapeutics (Switzerland and USA) and Vertex Inc (USA). Although this product is still in clinical development, it provides a good example of how gene editing can be used to modify stem cells, which can then be used to correct genetic defects in patients.
Neuroanesthésie et hypnose médicale
|Dr Gilda Pardey Bracho
|Anaesthetic management of awake craniotomy (neurosurgery) in patients with low-grade glioma.
La pathologie unguéale
|Dr Ameziane Chefai
L’insuffisance rénale chronique et les traitements de suppléance
|Dr Alexandre Karamé
|Introduction to renal physiology and pathophysiology, including glomerular diseases, chronic kidney failure (its stages and main causes) and renal replacement therapy.
Le trouble déficit de l’attention/hyperactivité (TDAH)
|Dr Marc-Antoine Crocq
|Attention deficit hyperactivity disorder (ADHD) affects 7% of children worldwide and 2.5% of adults. Diagnosis is primarily based on clinical symptoms. Women tend to display more symptoms of inattention and fewer hyperactivity symptoms. Undiagnosed ADHD generally has a negative impact on academic and social functioning. Effective treatment, both pharmacological and non-pharmacological, exists for ADHD. Several other disorders must be considered as a differential diagnosis or comorbidity for ADHD.
From molecular markers to precision oncology – emerging concepts and terms.
|Dr Katarzyna Szymanska
|Molecular biology, once considered to be ‘just’ a basic science with limited relevance to ‘real’ medicine, has been gaining its place in daily clinical practice. In oncology, molecular parameters are increasingly used to precisely define disease entities and guide treatment decisions. With the rapid development of new technologies, new data and new concepts are emerging at an impressive pace, and the quest for clinically useful biomarkers persists. In this presentation, I will define molecular biomarkers in the broad sense of the word, with an explanation of how they are identified and assessed, and what their clinical utility may be, with practical examples. I will also make a link between these biomarkers and what we call ‘precision medicine’ (here: precision oncology), at the same time pointing out to some common misconcepts about the latter and deciphering some related (not always correct) terms. Some technical issues related to the molecular analyses will be covered along the way. The presentation will be seasoned with multiple examples of texts you could be asked to translate.